IP Library Granted Patent US 9,351,997
Granted Patent B2
US 9,351,997 · App. 14/280,036 · Granted May 31, 2016

Method of treating cancer

Inventor: Lewis H. Bender (Westport, CT)
Assignee: Intensity Therapeutics, Inc.
A61K33/24A61K31/192A61K31/20A61K31/216A61K31/282A61K31/555A61K31/7032A61K31/7105A61K45/06A61K47/12A61K47/14A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,351,997
App. No.
14/280,036
Granted
May 31, 2016
Kind
B2
Abstract

The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

Claims (3)

1. A method of treating cancer in a subject in need of treatment, comprising: administering intratumorally an aqueous formulation including a therapeutically effective amount of a therapeutic agent and an intracellular permeation enhancing agent, wherein the formulation comprises cisplatin with N-(8[2-hydroxybenzoyl]amino)octanoic acid or cisplatin and vinblastine with N-(8[2-hydroxybenzoyl]amino)octanoic acid.

2. The method claim 1 , wherein the formulation is dosed at between 0.1 ml per cc of tumor volume and 1 ml per cc of tumor volume.

3. The method claim 1 , wherein the formulation comprises about 0.5 mg/ml of cisplatin with about 10 mg/ml of N-(8[2-hydroxybenzoyl]amino)octanoic acid or about 0.5 mg/ml of cisplatin and about 0.1 mg/ml of vinblastine with about 10 mg/ml of N-(8[2-hydroxybenzoyl]amino)octanoic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: BENDER, LEWIS H.
To: INTENSITY THERAPEUTICS, INC.
Reel/Frame 033064/0965 →
Continuity (5)
Continuation PCTUS2013059841 · Sep 15, 2013
Provisional Application 61779509 · Mar 13, 2013
Provisional Application 61707733 · Sep 28, 2012
Provisional Application 61703890 · Sep 21, 2012
Related Publication 20140248211A1 · Sep 4, 2014